SCHEMBL2474068

SCHEMBL2474068

c1cc2nc(-c3ccc4cc[nH]c4c3)cc(Nc3ccc(N4CCOCC4)cn3)n2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 2/20 0.47
▸ SYK P43405 11/20 0.46
▸ BTK Q06187 3/20 0.45
▸ PIK3CA P42336 4/20 0.42
▸ MTOR P42345 1/20 0.42
▸ PIK3CG P48736 1/20 0.42
▸ MAP3K11 Q16584 1/20 0.42
▸ TYK2 P29597 1/20 0.41
▸ NTRK1 P04629 1/20 0.40
▸ ROS1 P08922 1/20 0.40
▸ CSNK2A2 P19784 1/20 0.40
▸ FLT3 P36888 1/20 0.40
▸ CSNK2B P67870 1/20 0.40
▸ CSNK2A1 P68400 1/20 0.40
▸ PTK6 Q13882 1/20 0.40
▸ CSNK2A3 Q8NEV1 1/20 0.40
▸ IKBKE Q14164 1/20 0.40
▸ TBK1 Q9UHD2 1/20 0.40
▸ CCNE1 P24864 1/20 0.39
▸ CDK2 P24941 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13288359 0.90 SYK (0.59) JAK2SYKBTKNTRK1ROS1
SCHEMBL2474769 0.89 MAP3K11 (0.49) SYKBTKPIK3CAMTORMAP3K11
SCHEMBL18498989 0.83 CCND3 (0.41) JAK2SYKBTKTYK2IKBKE
SCHEMBL2475810 0.83 SYK (0.44) JAK2SYKBTKTYK2IKBKE
SCHEMBL2473718 0.82 SYK (0.45) JAK2SYKTYK2CCNE1CDK2
SCHEMBL2478695 0.81 SYK (0.42) SYK
SCHEMBL2476464 0.81 SYK (0.47) JAK2SYKBTKMTORTYK2
SCHEMBL18499161 0.81 TYK2 (0.38) JAK2SYKBTKTYK2FLT3
SCHEMBL18499163 0.81 TYK2 (0.38) JAK2SYKBTKTYK2FLT3
SCHEMBL2471685 0.76 SYK (0.58) JAK2SYKBTKNTRK1ROS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9567348-B2 Substituted pyrazolo[1,5-a]pyrimidines as Syk inhibitors GILEAD CONNECTICUT, INC. (US) 2017-02-14 — — US claimed
US-20150266902-A1 IMIDAZOPYRAZINE SYK INHIBITORS Kronos Bio, Inc. 2015-09-24 — — US claimed
US-20130231330-A1 IMIDAZOPYRIZINE SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2013-09-05 — — US claimed
EP-2373318-A1 IMIDAZOPYRAZINE SYK INHIBITORS Gilead Connecticut, Inc. (US) 2011-10-12 — — EP claimed
WO-2010068258-A1 IMIDAZOPYRAZINE SYK INHIBITORS CGI PHARMACEUTICALS, INC. (US) 2010-06-17 — — WO claimed
US-20100152159-A1 IMIDAZOPYRAZINE SYK INHIBITORS Kronos Bio, Inc. 2010-06-17 — — US claimed
EP-3552607-A2 IMIDAZOPYRAZINE SYK INHIBITORS Gilead Connecticut, Inc. (US) 2019-10-16 — — EP disclosed
EP-3552607-A2 IMIDAZOPYRAZINE SYK INHIBITORS Gilead Connecticut, Inc. (US) 2019-10-16 — — EP disclosed
EP-2373318-B1 IMIDAZOPYRAZINE SYK INHIBITORS GILEAD CONNECTICUT INC (US) 2019-06-05 — — EP disclosed
EP-2373318-B1 IMIDAZOPYRAZINE SYK INHIBITORS GILEAD CONNECTICUT INC (US) 2019-06-05 — — EP disclosed
US-10093684-B2 Substituted imidazo[1,2-a]pyrazines as Syk inhibitors GILEAD CONNECTICUT, INC. (US) 2018-10-09 — — US disclosed
US-20170121350-A1 IMIDAZOPYRAZINE SYK INHIBITORS Kronos Bio, Inc. 2017-05-04 — — US disclosed
US-20170121350-A1 IMIDAZOPYRAZINE SYK INHIBITORS Kronos Bio, Inc. 2017-05-04 — — US disclosed
US-8440667-B2 Imidazopyrazine Syk inhibitors GILEAD CONNECTICUT, INC. (US) 2013-05-14 — — US disclosed
US-8440667-B2 Imidazopyrazine Syk inhibitors GILEAD CONNECTICUT, INC. (US) 2013-05-14 — — US disclosed
US-8440667-B2 Imidazopyrazine Syk inhibitors GILEAD CONNECTICUT, INC. (US) 2013-05-14 — — US disclosed
WO-2010068258-A1 IMIDAZOPYRAZINE SYK INHIBITORS CGI PHARMACEUTICALS, INC. (US) 2010-06-17 — — WO disclosed
US-20100152159-A1 IMIDAZOPYRAZINE SYK INHIBITORS Kronos Bio, Inc. 2010-06-17 — — US disclosed
US-20100152159-A1 IMIDAZOPYRAZINE SYK INHIBITORS Kronos Bio, Inc. 2010-06-17 — — US disclosed
US-20100152159-A1 IMIDAZOPYRAZINE SYK INHIBITORS Kronos Bio, Inc. 2010-06-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266902-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 JAK2 16/4885SYK 1/4885BTK 2/4885
US-10093684-B2 Substituted imidazo[1,2-a]pyrazines as Syk inhibitors SYK, BTK, ZAP70 JAK2 13/4885SYK 1/4885BTK 2/4885
US-20130231330-A1 IMIDAZOPYRIZINE SYK INHIBITORS SYK, ZAP70, BTK JAK2 18/4885SYK 1/4885BTK 3/4885
US-20170121350-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 JAK2 16/4885SYK 1/4885BTK 2/4885
US-20100152159-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 JAK2 16/4885SYK 1/4885BTK 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback